X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs ABBOTT INDIA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE ABBOTT INDIA CADILA HEALTHCARE/
ABBOTT INDIA
 
P/E (TTM) x 19.5 40.2 48.6% View Chart
P/BV x 4.6 10.3 44.7% View Chart
Dividend Yield % 0.9 0.7 132.6%  

Financials

 CADILA HEALTHCARE   ABBOTT INDIA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
ABBOTT INDIA
Mar-18
CADILA HEALTHCARE/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs5586,110 9.1%   
Low Rs3623,996 9.0%   
Sales per share (Unadj.) Rs116.31,552.2 7.5%  
Earnings per share (Unadj.) Rs17.9188.8 9.5%  
Cash flow per share (Unadj.) Rs23.1196.4 11.8%  
Dividends per share (Unadj.) Rs3.5055.00 6.4%  
Dividend yield (eoy) %0.81.1 69.9%  
Book value per share (Unadj.) Rs85.4796.6 10.7%  
Shares outstanding (eoy) m1,023.7421.25 4,817.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.03.3 121.4%   
Avg P/E ratio x25.726.8 96.1%  
P/CF ratio (eoy) x19.925.7 77.3%  
Price / Book Value ratio x5.46.3 84.9%  
Dividend payout %19.629.1 67.2%   
Avg Mkt Cap Rs m470,664107,376 438.3%   
No. of employees `00011.83.3 355.8%   
Total wages/salary Rs m18,5453,937 471.1%   
Avg. sales/employee Rs Th10,072.79,929.3 101.4%   
Avg. wages/employee Rs Th1,569.11,185.1 132.4%   
Avg. net profit/employee Rs Th1,547.71,207.7 128.1%   
INCOME DATA
Net Sales Rs m119,04932,985 360.9%  
Other income Rs m1,1321,170 96.8%   
Total revenues Rs m120,18134,155 351.9%   
Gross profit Rs m28,4755,245 542.9%  
Depreciation Rs m5,388162 3,328.0%   
Interest Rs m91138 2,384.8%   
Profit before tax Rs m23,3086,215 375.0%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6442,203 256.2%   
Profit after tax Rs m18,2924,012 455.9%  
Gross profit margin %23.915.9 150.4%  
Effective tax rate %24.235.4 68.3%   
Net profit margin %15.412.2 126.3%  
BALANCE SHEET DATA
Current assets Rs m82,00522,655 362.0%   
Current liabilities Rs m60,7206,681 908.9%   
Net working cap to sales %17.948.4 36.9%  
Current ratio x1.43.4 39.8%  
Inventory Days Days7365 112.9%  
Debtors Days Days9829 337.2%  
Net fixed assets Rs m83,703835 10,018.7%   
Share capital Rs m1,024213 481.9%   
"Free" reserves Rs m86,42116,715 517.0%   
Net worth Rs m87,44516,928 516.6%   
Long term debt Rs m25,5510-   
Total assets Rs m180,65324,162 747.7%  
Interest coverage x26.6163.7 16.2%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.71.4 48.3%   
Return on assets %10.616.8 63.4%  
Return on equity %20.923.7 88.3%  
Return on capital %22.036.9 59.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,683369 11,581.6%   
Fx outflow Rs m11,2423,807 295.3%   
Net fx Rs m31,441-3,438 -914.5%   
CASH FLOW
From Operations Rs m9,1931,527 602.0%  
From Investments Rs m-9,737-2,148 453.2%  
From Financial Activity Rs m515-1,024 -50.3%  
Net Cashflow Rs m-29-1,646 1.8%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.3 7.9 105.1%  
FIIs % 5.9 0.1 5,900.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 17.1 64.3%  
Shareholders   44,069 18,270 241.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Stock Market's Sudden Crash; Rising Oil Prices; Banking Stocks and Top Cues in Action Today(Pre-Open)

The Indian share markets ended lower on Friday. The S&P BSE Sensex partially recovered after crashing 1,000 points in intraday trade to settle 280 points lower.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Sep 21, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS